Mizuho raised the firm’s price target on Axsome Therapeutics (AXSM) to $202 from $200 and keeps an Outperform rating on the shares. The company reported strong Q3 results with sales beats for both Auvelity and Sunosi, the analyst tells investors in a research note.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXSM:
- Axsome Therapeutics management to meet with Truist
- Axsome Therapeutics’ Earnings Call Highlights Growth and Challenges
- Axsome Therapeutics price target raised to $198 from $189 at RBC Capital
- Axsome Therapeutics price target raised to $185 from $180 at H.C. Wainwright
- Axsome Therapeutics price target raised to $196 from $194 at Morgan Stanley